Teresa Whalen, CEO

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, Influenza and other viral infectious diseases.

https://www.cytoagents.com/

John Edwards, CEO

Drusolv Threapeuticis is a clinical-stage drug company developing a high-dose oral statin for early intervention in age-related macular degeneration (AMD).

Lillian W. Chiang, Ph.D., President & CEO

Evrys Bio antivirals target non-viral human proteins, known as sirtuins, enhancing their natural ability to fight powerful infections.

Home

Matt Handel, CEO

ExpressCells leverages proprietary gene-editing tools and the power of CRISPR to create custom, knock-in cell lines for drug discovery, toxicology, and other biologic research.

https://xpresscells.com/

Greg Bosch, CEO

Developing a product for cancers with high unmet need; e.g., pancreatic, ovarian, mesotheliomas, triple negative breast and other cancers.

https://www.geistlich-na.com/

Renee Stewart, Co-Founder & CSO

Developing innovative therapeutic products for patients suffering from illnesses associated with rheumatology, immunology and oncology.

http://www.levoltapharma.com/

Joshua McClure, CEO

Maxwell Biosciences is a preclinical stage drug platform company actively developing an entirely new class of patented, virucidal, small molecule drugs called Maxwell’s Peptoids™.

https://maxwellbiosciences.com/

Thomas Tillett, CEO

MBF Therapeutics is a life science company focused on the development of gene-based, immunotherapeutic vaccines for use in veterinary medicine and human health.

https://www.mbftherapeutics.com/

Yarom Cohen, CEO

Seed stage company developing new drugs to treat obesity, metabolic syndrome, different forms of cancer, Alzheimer’s Disease and Parkinson’s Disease.

www.met-syn-lysine.com

Nikolaos Tezapsidis, CEO

Neurotez, Inc. is a private corporation whose primary goal is to develop a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.

http://neurotez.com

Keith Ignotz, CEO

Proprietary technology based on a novel drug-eluting contact lens to provide timed drug delivery directly to eye; improving recovery, reducing cost for millions after eye surgery and LASIK.

http://ocumedic.us/

Sebastian Franzinger, VP, Finance & Business Development

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class compounds that selectively target G protein-coupled receptors for oncology.

HOME

Mahesh Narayanan, CEO

PepVax, Inc. is an early-stage biotechnology company developing a novel DNA plasmid delivery system using the patient’s own cells to manufacture the required proteins, T-cells and antibodies in vivo for cancers, infectious and genetic diseases.

http://www.pepvax.co/

Zeev Dvashi, CEO

Plas-Free focuses on the development of an innovative medical device ClearPlasma™ that modifies human plasma to improve treatment for massive bleeding.

https://www.plas-free.com/

Kelly Beck, CEO

PolyCore Therapeutics is developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders. PolyCore is currently conducting preclinical studies for a novel small molecule for treatment of Parkinson’s Disease.

Home

Ira Spector, CEO

SFA Therapeutics, Inc. is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of chronic inflammatory disease– the use of microbiome-derived metabolites as drugs.

https://sfatherapeutics.com/

Yoel Shiboleth, CEO & Co-Founder

Developing cell therapies for immune disorders, cancer and genetic diseases. TargetGene is a pioneer in the field of genome editing and owns the first RNA-guided nuclease system ever invented.

https://targetgenebio.com/

Andrew Luber, President & CEO, Director

Commited to developing innovative immune-based treatments for virally associated cancers and chronic viral infections utilizing the first genetic construct checkpoint inhibitor given via vaccination.

https://www.viriontx.com/

Charlotte D’Hulst, CEO

Developing a technology platform by merging the biology of the nose with cutting-edge chip nanotechnology for odor-based disease diagnostics.

Home